Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic
NCT ID: NCT03704623
Last Updated: 2020-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2019-05-01
2020-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
NCT00553605
Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations
NCT01685658
Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics
NCT02304783
NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain Management
NCT03222518
Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics
NCT05722782
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Visual Analogue Scale (VAS) will be calculated on presentation and at 30 minutes after analgesia administration. Patients who do not respond to an initial dose of the analgesia will receive rescue analgesia in the form of Morphine, 01.mg/kg, IV.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paracetamol
Patients will receive IV 1 g of Paracetamol
Paracetamol
Paracetamol 1g IV
Parecoxib
Patients will receive 40 mg of Parecoxib IV
Parecoxib
Parecoxib 40 mg IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paracetamol
Paracetamol 1g IV
Parecoxib
Parecoxib 40 mg IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of peptic ulcer.
* Pregnant or breastfeeding females.
* Patients with hepatic impairment (Child-Pugh score \>10).
* Patients with chronic kidney disease (CKD) Stage 4 or 5 (eGFR \<30mls/min).
* History of coronary ischemia, peripheral vascular or cerebrovascular disease.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amiri Hospital
OTHER_GOV
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed R. EL-Nahas
Professor of Urology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdullatif AL-Terki, MD
Role: STUDY_CHAIR
Amiri Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Amiri Hospital
Kuwait City, , Kuwait
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Parecoxib vs Paracetamol
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.